Zacks: Analysts Expect Steris PLC (NYSE:STE) to Post $1.11 EPS

Equities analysts predict that Steris PLC (NYSE:STE) will announce earnings of $1.11 per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Steris’ earnings. The lowest EPS estimate is $1.11 and the highest is $1.12. Steris reported earnings per share of $1.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 11%. The company is expected to report its next quarterly earnings report after the market closes on Monday, August 5th.

On average, analysts expect that Steris will report full-year earnings of $5.37 per share for the current fiscal year, with EPS estimates ranging from $5.35 to $5.40. For the next year, analysts expect that the company will report earnings of $5.93 per share, with EPS estimates ranging from $5.90 to $5.99. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Steris.

Steris (NYSE:STE) last released its quarterly earnings data on Monday, May 13th. The medical equipment provider reported $1.53 EPS for the quarter, beating the consensus estimate of $1.44 by $0.09. The company had revenue of $768.00 million during the quarter, compared to the consensus estimate of $738.87 million. Steris had a return on equity of 13.34% and a net margin of 10.93%. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.24 EPS.

Several research firms have recently commented on STE. Zacks Investment Research raised Steris from a “hold” rating to a “buy” rating and set a $146.00 price objective for the company in a report on Tuesday, April 30th. Stephens increased their price objective on Steris from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, May 15th. KeyCorp increased their price objective on Steris from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Wednesday, May 15th. Finally, JMP Securities increased their price objective on Steris from $135.00 to $150.00 and gave the company a “market outperform” rating in a report on Wednesday, May 22nd. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $148.20.

Shares of NYSE STE remained flat at $$148.86 during trading hours on Thursday. The stock had a trading volume of 184,532 shares, compared to its average volume of 414,254. The company has a market capitalization of $12.71 billion, a PE ratio of 30.44 and a beta of 1.00. The company has a quick ratio of 1.82, a current ratio of 2.27 and a debt-to-equity ratio of 0.37. Steris has a 12 month low of $99.14 and a 12 month high of $154.09. The business’s fifty day moving average price is $147.53.

In related news, VP Karen L. Burton sold 1,387 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $133.89, for a total value of $185,705.43. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 119,000 shares of the stock in a transaction on Friday, May 31st. The shares were sold at an average price of $132.56, for a total value of $15,774,640.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 244,145 shares of company stock worth $33,121,338. 2.36% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fort L.P. increased its position in Steris by 23.6% during the 1st quarter. Fort L.P. now owns 19,561 shares of the medical equipment provider’s stock worth $2,504,000 after buying an additional 3,733 shares during the period. Amundi Pioneer Asset Management Inc. increased its position in Steris by 6.9% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 65,660 shares of the medical equipment provider’s stock worth $7,016,000 after buying an additional 4,229 shares during the period. Neuburgh Advisers LLC increased its position in Steris by 22.5% during the 1st quarter. Neuburgh Advisers LLC now owns 11,748 shares of the medical equipment provider’s stock worth $1,505,000 after buying an additional 2,156 shares during the period. Texas Permanent School Fund increased its position in Steris by 3.9% during the 1st quarter. Texas Permanent School Fund now owns 57,433 shares of the medical equipment provider’s stock worth $7,353,000 after buying an additional 2,137 shares during the period. Finally, Twin Capital Management Inc. increased its position in Steris by 0.6% during the 1st quarter. Twin Capital Management Inc. now owns 34,440 shares of the medical equipment provider’s stock worth $4,409,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 83.98% of the company’s stock.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Recommended Story: Trading Ex-Dividend

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.